As Chief Business Officer, Chris Meda has thirty years of leadership in the diagnostic and pharmaceutical industries. Her management responsibilities have included the creation of strategic business direction and plans; operations and commercialization of more than thirty products for various disease areas at Hoffman-LaRoche, Bio-Rad Laboratories, Diagnostics Products Corporation (now Siemens), Meridian Diagnostics and Schering AG pharmaceuticals.
Chris also serves as a Chair on Women in BIO – San Francisco Chapter, an organization of professionals committed to promoting careers, leadership, and entrepreneurship of women in the life sciences; and as Board Director for Claremont BioSolutions, a company providing laboratories with diagnostics and devices for molecular diagnostics and bioscience research.
Prior to IncellDx, Chris was President of Response Genetics (RGI), a precision medicine company that has developed PCR-based genetics tests for lung, colon, gastric and melanoma cancers.
Creating a Coordinated Path Forward: Biomarkers in Drug Discovery and Clinical Practice
2:05 PM - 2:55 PM